Summary: A large genetic analysis reveals that cannabis use disorder (CanUD) shares substantial genetic overlap with several psychiatric conditions — including major depression, PTSD, ADHD and schizophrenia — and differs genetically from casual cannabis use. Using global and local genetic correlations, colocalization, Mendelian randomization and genomic structural equation modeling, researchers identified distinct genetic signatures for CanUD and evidence of bidirectional relationships with many psychiatric disorders.
The results suggest that heavy, prolonged cannabis use that progresses to CanUD may both reflect and amplify genetic vulnerability to mental illness. As cannabis becomes more widely used and legalized, these findings underscore the need for targeted prevention and careful clinical assessment of at-risk individuals.
Key Facts
- CanUD genetics: Cannabis use disorder shows far stronger genetic overlap with multiple psychiatric disorders than casual cannabis use.
- Bidirectional risk: Genetic evidence indicates two-way causal influences between CanUD and many psychiatric conditions, creating a potential feedback loop of risk.
- Shared variants: Specific genomic regions, including loci near CHRNA2 linked to nicotinic receptors, are implicated in both CanUD and schizophrenia.
Source: Neuroscience News
As legal access and social acceptance of cannabis grow, use has increased for both recreational and medicinal purposes. While many users experience no serious problems, growing genetic evidence indicates that heavy or compulsive cannabis use can be tied to heightened psychiatric risk—especially when it develops into cannabis use disorder (CanUD).
A comprehensive genetic study now clarifies how casual cannabis use, CanUD, and a range of psychiatric and personality traits relate at the genomic level. The investigators compared genetic patterns for lifetime cannabis use and clinically defined CanUD against multiple psychiatric outcomes including schizophrenia, bipolar disorder, major depression, anxiety disorders, ADHD and PTSD.
The analysis revealed clear distinctions between the genetics of simple cannabis use and those of CanUD, shedding light on why only a subset of users progress to severe problems and mental health comorbidity.
Cannabis Use versus Cannabis Use Disorder
Cannabis can produce calming or therapeutic effects for some people, but sustained heavy use can lead to CanUD, marked by compulsive consumption despite adverse consequences. In the United States, more than 16 million people meet criteria for CanUD each year, highlighting a substantial public-health burden.
Although lifetime cannabis use and CanUD are moderately correlated, their genetic architectures differ markedly. Both traits show some links to psychiatric risk, but CanUD demonstrates much stronger and broader genetic overlap across nearly every psychiatric disorder examined.
CanUD had particularly strong genetic correlations with ADHD, major depressive disorder, schizophrenia, bipolar disorder, PTSD and anxiety. Personality dimensions such as neuroticism and low agreeableness were also more closely connected to CanUD than to casual use. By contrast, simple cannabis use had weaker, and in many cases absent, genetic associations with the same psychiatric traits.
An example of divergent patterns: casual cannabis use showed a modest genetic correlation with anorexia nervosa, while CanUD did not — suggesting distinct biological pathways underlie body-weight–related traits versus addiction vulnerability.
Evidence for Causal Relationships
Genetic correlation does not establish causality, so the researchers applied Mendelian randomization to infer directional effects. This approach treats genetic variants as natural instruments to test whether one trait causally influences another.
Mendelian randomization indicated bidirectional causal links between CanUD and most psychiatric disorders tested: CanUD increases risk for conditions such as schizophrenia, depression, ADHD and PTSD, and those disorders in turn elevate risk for developing CanUD. This two-way relationship suggests vulnerable individuals may enter cycles in which psychiatric symptoms and compulsive cannabis use mutually reinforce each other.
By contrast, lifetime cannabis use showed little evidence of causing psychiatric disorders, with ADHD being a notable exception. On the other hand, psychiatric illnesses such as schizophrenia and bipolar disorder increased the likelihood of cannabis use, consistent with the hypothesis that some individuals use cannabis to self-medicate symptoms despite potential long-term harm.
Genetic Fingerprints and Overlapping Loci
Beyond correlation and causality, the study pinpointed genomic regions shared between CanUD and psychiatric disorders. Colocalization and local genetic correlation analyses identified overlapping variants that may drive risk across traits.
One notable shared signal was located near a gene regulating CHRNA2, which affects nicotinic acetylcholine receptors in the brain — receptors that have been implicated in smoking behavior and other addictive processes. Such overlap points to common biological mechanisms linking substance use vulnerability and psychiatric illness, and suggests that effective treatment might need to address both domains.
Public-Health and Clinical Implications
These findings have important implications for public health messaging, clinical screening, and policy. Cannabis is sometimes promoted as a treatment for conditions like PTSD or depression; in some U.S. states it is even approved for use in certain psychiatric contexts. However, genetic evidence that CanUD can exacerbate psychiatric disorders in susceptible individuals argues for caution.
The distinction between casual cannabis use and CanUD is critical: while occasional use appears less tied to psychiatric risk, progression to problematic, compulsive use unleashes stronger genetic liabilities that can amplify mental-health problems. Policy and clinical practice should therefore emphasize prevention of heavy use and early identification of individuals at elevated risk.
Future Directions
These genetic insights open paths to more personalized prevention and treatment strategies. Screening for genetic vulnerability to CanUD and co-occurring psychiatric disorders could guide counseling and risk-reduction efforts. Moreover, understanding shared biological pathways may help identify medications or behavioral interventions that target both addiction and psychiatric symptoms.
The Bottom Line
The study provides a nuanced message: cannabis is not uniformly dangerous, but the transition from use to cannabis use disorder carries substantially greater genetic risk for psychiatric illness. As legalization spreads, education and clinical screening should communicate this complexity—warning about the dangers of heavy, compulsive use while avoiding stigma for responsible adult users.
Clinicians should screen patients with psychiatric disorders for CanUD and monitor cannabis-using patients for emerging psychiatric symptoms, given the bidirectional genetic relationships identified.
About this genetics, CUD, and mental health research news
Author: Neuroscience News Communications
Source: Neuroscience News
Contact: Neuroscience News Communications – Neuroscience News
Image: The image is credited to Neuroscience News
Source: Open access.
“The genetic relationship between cannabis use disorder, cannabis use and psychiatric disorders” by Marco Galimberti et al., Nature Mental Health
Abstract
The genetic relationship between cannabis use disorder, cannabis use and psychiatric disorders
Rising rates of cannabis use and cannabis use disorder (CanUD) may contribute to increased prevalence of psychiatric disorders. This study assessed relationships between lifetime cannabis use, CanUD and a broad set of psychiatric traits using global and local genetic correlation, genomic structural equation modeling, colocalization analyses and Mendelian randomization to probe causality.
Global genetic analyses revealed significantly different correlation profiles for CanUD compared with casual cannabis use. A variant in strong linkage disequilibrium with a regulator of CHRNA2 was shared by CanUD and schizophrenia in colocalization analysis and appeared in a genomic region showing significant local genetic correlation between these traits. A three-factor genomic structural equation model indicated that CanUD and cannabis use partially load onto a factor that also includes major depressive disorder and ADHD. Mendelian randomization supported bidirectional causal relationships between CanUD and most psychiatric disorders tested, a pattern not observed for casual cannabis use. Overall, rising cannabis consumption and progression to CanUD may increase rates of psychiatric disorders over time, particularly among individuals who develop problematic use.